An Open Label, Non-Randomized, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1349572 20 mg, Administered as a Single Oral Suspension Dose to Healthy Adult Subjects (ING111853).
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 12 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Mar 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 30 Jan 2009 New trial record